Literature DB >> 27936955

Sequence variations in C9orf72 downstream of the hexanucleotide repeat region and its effect on repeat-primed PCR interpretation: a large multinational screening study.

Angelica Nordin1, Chizuru Akimoto2, Anna Wuolikainen3,4, Helena Alstermark1, Karin Forsberg5, Peter Baumann6, Susana Pinto7, Mamede de Carvalho7,8, Annemarie Hübers9, Frida Nordin1, Albert C Ludolph9, Jochen H Weishaupt9, Thomas Meyer10, Torsten Grehl11, Kathi Schweikert12, Markus Weber13, Christian Burkhardt13, Christoph Neuwirth13, Trygve Holmøy14,15, Mitsuya Morita2, Ole-Bjørn Tysnes16,17, Michael Benatar18, Joanne Wuu18, Dale J Lange19,20, Carsten Bisgård21, Nasrin Asgari21,22, Ilkka Tarvainen23, Thomas Brännström5, Peter M Andersen1,9.   

Abstract

A large GGGGCC-repeat expansion mutation (HREM) in C9orf72 is the most common known cause of ALS and FTD in European populations. Sequence variations immediately downstream of the HREM region have previously been observed and have been suggested to be one reason for difficulties in interpreting RP-PCR data. Our objective was to determine the properties of these sequence variations with regard to prevalence, the range of variation, and effect on disease prognosis. We screened a multi-national cohort (n = 6981) for the HREM and samples with deviant RP-PCR curves were identified. The deviant samples were subsequently sequenced to determine sequence alteration. Our results show that in the USA and European cohorts (n = 6508) 10.7% carried the HREM and 3% had a sequence variant, while no HREM or sequence variants were observed in the Japanese cohort (n = 473). Sequence variations were more common on HREM alleles; however, certain population specific variants were associated with a non-expanded allele.In conclusion, we identified 38 different sequence variants, most located within the first 50 bp downstream of the HREM region. Furthermore, the presence of an HREM was found to be coupled to a lower age of onset and a shorter disease survival, while sequence variation did not have any correlation with these parameters.

Entities:  

Keywords:  ALS; C9orf72; FTD; RP-PCR interpretation; variants

Mesh:

Substances:

Year:  2016        PMID: 27936955     DOI: 10.1080/21678421.2016.1262423

Source DB:  PubMed          Journal:  Amyotroph Lateral Scler Frontotemporal Degener        ISSN: 2167-8421            Impact factor:   4.092


  9 in total

1.  Comprehensive genotyping of the C9orf72 hexanucleotide repeat region in 2095 ALS samples from the NINDS collection using a two-mode, long-read PCR assay.

Authors:  Eran Bram; Kamyab Javanmardi; Kimberly Nicholson; Kristen Culp; Julie R Thibert; Jon Kemppainen; Vivian Le; Annette Schlageter; Andrew Hadd; Gary J Latham
Journal:  Amyotroph Lateral Scler Frontotemporal Degener       Date:  2018-11-15       Impact factor: 4.092

2.  Validation of a Long-Read PCR Assay for Sensitive Detection and Sizing of C9orf72 Hexanucleotide Repeat Expansions.

Authors:  EunRan Suh; Kaitlyn Grando; Vivianna M Van Deerlin
Journal:  J Mol Diagn       Date:  2018-08-20       Impact factor: 5.568

3.  C9orf72 Intermediate Alleles in Patients with Amyotrophic Lateral Sclerosis, Systemic Lupus Erythematosus, and Rheumatoid Arthritis.

Authors:  Micaela Fredi; Ilaria Cavazzana; Giorgio Biasiotto; Massimiliano Filosto; Alessandro Padovani; Eugenio Monti; Angela Tincani; Franco Franceschini; Isabella Zanella
Journal:  Neuromolecular Med       Date:  2019-03-11       Impact factor: 3.843

4.  High frequency of C9orf72 hexanucleotide repeat expansion in amyotrophic lateral sclerosis patients from two founder populations sharing the same risk haplotype.

Authors:  Orly Goldstein; Mali Gana-Weisz; Beatrice Nefussy; Batel Vainer; Omri Nayshool; Anat Bar-Shira; Bryan J Traynor; Vivian E Drory; Avi Orr-Urtreger
Journal:  Neurobiol Aging       Date:  2017-12-27       Impact factor: 4.673

Review 5.  Expanding Clinical Spectrum of C9ORF72-Related Disorders and Promising Therapeutic Strategies: A Review.

Authors:  Sarah Breevoort; Summer Gibson; Karla Figueroa; Mark Bromberg; Stefan Pulst
Journal:  Neurol Genet       Date:  2022-04-29

6.  Sizing, stabilising, and cloning repeat-expansions for gene targeting constructs.

Authors:  Remya R Nair; Charlotte Tibbit; David Thompson; Ross McLeod; Asif Nakhuda; Michelle M Simon; Robert H Baloh; Elizabeth M C Fisher; Adrian M Isaacs; Thomas J Cunningham
Journal:  Methods       Date:  2020-07-25       Impact factor: 3.608

7.  Targeting RNA-Mediated Toxicity in C9orf72 ALS and/or FTD by RNAi-Based Gene Therapy.

Authors:  Raygene Martier; Jolanda M Liefhebber; Ana García-Osta; Jana Miniarikova; Mar Cuadrado-Tejedor; Maria Espelosin; Susana Ursua; Harald Petry; Sander J van Deventer; Melvin M Evers; Pavlina Konstantinova
Journal:  Mol Ther Nucleic Acids       Date:  2019-02-11

8.  Poly-glycine-alanine exacerbates C9orf72 repeat expansion-mediated DNA damage via sequestration of phosphorylated ATM and loss of nuclear hnRNPA3.

Authors:  Yoshihiro Nihei; Kohji Mori; Georg Werner; Thomas Arzberger; Qihui Zhou; Barham Khosravi; Julia Japtok; Andreas Hermann; Andreas Sommacal; Markus Weber; Frits Kamp; Brigitte Nuscher; Dieter Edbauer; Christian Haass
Journal:  Acta Neuropathol       Date:  2019-10-23       Impact factor: 17.088

Review 9.  Unravelling the clinical spectrum and the role of repeat length in C9ORF72 repeat expansions.

Authors:  Emma L van der Ende; Jazmyne L Jackson; Marka van Blitterswijk; John C Van Swieten; Adrianna White; Harro Seelaar
Journal:  J Neurol Neurosurg Psychiatry       Date:  2021-01-15       Impact factor: 10.154

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.